Please login to the form below

Not currently logged in
Email:
Password:

Meda appoints Maria Carell regional director for the US

She joins the Swedish speciality pharma company with management experience from Novartis, Actavis and Q-Med

Swedish speciality pharma company Meda has appointed Maria Carell to a senior management position at its US operations.

She has sat on the firm's board for almost a year and will now take up the role of regional director for the US as Meda waits for a decision from the Food and Drug Administration (FDA) on its rhinitis treatment Dymista.

The US regulator is due to decide in early May on Dymista (azelastine hydrochloride and fluticasone propionate), a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.

"Maria Carell will be an important addition to the team that prepares the launch of Dymista in the US", said Anders Lönner, Meda's CEO.

She joins Meda with extensive experience in the health care sector, including management positions at Novartis, generics company Actavis and medical device firm Q-Med.

Following Carell's appointment to the US regional role she has declined re-election to Meda's board.

18th April 2012

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, market access, healthcare digital excellence, and strategic consultancy. We bring...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....